HANOVER, Germany--(BUSINESS WIRE)--Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced ...

Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platform Company has analyzed over 360 Billion heartbeats and ...

In the left part can be seen multi-omics analysis suggested some proteins (histone / non-histone), protein lactylation, and genes change significantly at different developmental stages (1 w [week], 6 ...

Researchers at the UNC School of Medicine, UNC McAllister Heart Institute, and the UNC Lineberger Comprehensive Cancer Center characterized the expression of thousands of cardiac proteins during eight ...

When the workload on the heart increases, the ventricular wall may thicken too, known as cardiac hypertrophy. This is an adaptive response that reduces pressure on the heart and maintains the activity ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...